NUCLIDIUM Announces Closing of Series B Extension Bringing Total Round to CHF 105 Million
CHF 26.4 million (EUR 28.4 million) extension, led by existing investors, accelerates clinical development of NU101 and NU201 radiotheranostic programs in metastatic castration resistant prostate cancer and metastatic breast cancer Basel, Switzerland …